Verapamil effect on COPD

The effect of verapamil nebulizer on oxygenation in COPD patients admitted to ICU

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170210032478N1

Enrollment

Registered

2018-06-05

Start date

2018-05-31

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease. Diseases of the respiratory system

Interventions

Intervention group: Inhalation of Verapamil.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All ICU- admitted COPD patients

Exclusion criteria

Exclusion criteria: pregnancy sever hepato renal dysfunction AV block or arrythmia EF less than 40% verapamil hypersensitivity beta-adrenergic receptor drugs QT disorders in patients Bradycardia co- administration of Digoxin

Design outcomes

Primary

Measure	Time frame
Arterial Oxygenation Blood gaz. Timepoint: 20 minutes after taking the medication or placebo for 3 days, Q 12 h. Method of measurement: Arterial Blood Gaz.;BORG scale. Timepoint: 20 minutes after taking the medication or placebo for 3 days, Q 12 h. Method of measurement: Tacking History.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariba Ghorbani

National Research Institute of Tuberculosis and Lung Diseases

dr.f.ghorbani@sbmu.ac.ir+98 21 2712 2163

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026